Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand

Eli Lilly became the first drugmaker to reach a $1 trillion market capitalization as its stock has rallied on surge in demand for tirzepatide products Mounjaro and Zepbound, with obesity and diabetes sales generating more than $10.09 billion—over half of last quarter’s $17.6 billion revenue—and driving a year-to-date rise of more than 35% and a roughly 75% gain since Zepbound’s late-2023 launch. Investors are pricing in durable growth—Lilly trades near 50x forward earnings—as the weight-loss market is forecast to be as large as $150 billion by 2030 and the company advances an oral candidate, orforglipron, due for potential approval next year. A recent U.S. production and pricing deal could broaden access (potentially adding millions of candidates) but may cap near-term revenues, so the market will be watching whether Lilly can sustain volume and margin expansion amid pricing pressure and scale-up risks.

Analysis

Eli Lilly reached a $1 trillion market capitalization on Friday, becoming the first drugmaker to enter that club after a more than 35% year-to-date rally and roughly a 75% gain since Zepbound's late-2023 launch; shares were trading near $1,051 and the stock commands about 50x anticipated next-12-month earnings per LSEG data. The move is driven by the tirzepatide franchise (Mounjaro for type 2 diabetes and Zepbound for obesity), which generated over $10.09 billion in the latest reported quarter and accounted for more than half of total revenue of $17.6 billion. Lilly upgraded its annual revenue guidance by more than $2 billion at the midpoint in October and the market is pricing durable demand ahead of an expected early‑next‑year approval of oral orforglipron, which Citi believes can leverage the injectable predecessors' momentum. Key risks that could reverse sentiment include pricing pressure from the U.S. government deal (which expands access to an estimated 40 million potential candidates but may cap near‑term revenue), execution and manufacturing scale‑up challenges, and competitive dynamics with Novo Nordisk that could compress margins and slow price realization.

Key Decisions for Investors

• Consider a measured overweight to capture continued growth from Lilly's tirzepatide franchise, but size exposure conservatively given the ~50x forward multiple
• Use the FDA decision on orforglipron and the next several quarterly revenue/margin prints as primary catalysts for adding or trimming risk
• Monitor the U.S. pricing deal's real‑world impact on volumes and realized prices over the next 2–4 quarters and be prepared to reduce exposure if margins deteriorate materially
• Employ downside protection (e.g., options hedges or stop rules) to guard against execution misses, manufacturing setbacks, or renewed competitive pressure from Novo Nordisk